Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote

Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote

The lack of "OMG" bombshells in the FDA's neratinib review are a Monday win for Puma bulls, and the stock is soaring.

Amgen Osteoporosis Drug Approval Plan Derailed Over Heart Safety Risk -- Jim Cramer Weighs In

Amgen Osteoporosis Drug Approval Plan Derailed Over Heart Safety Risk -- Jim Cramer Weighs In

Amgen's osteoporosis setback will likely be seen as a providing a commercial boost to Radius Health, which secured U.S. approval in April for a competing osteoporosis drug, Tymlos.

Mixed Outcomes for La Jolla Pharma Shock Drug Fuels Debate Over Sales Potential

Mixed Outcomes for La Jolla Pharma Shock Drug Fuels Debate Over Sales Potential

LJPC-501 reversed dangerously low blood pressure in patients suffering from a severe form of shock, but the drug did not improve total organ function or reduce mortality.

Incyte Shares Vault After 'IDO' Cancer Immunotherapy Combo Data Revealed

Incyte Shares Vault After 'IDO' Cancer Immunotherapy Combo Data Revealed

The new Incyte data revealed ahead of the ASCO meeting in June involve combination therapies with Merck and Bristol-Myers Squibb in multiple types of cancer.

Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting

Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting

The drug companies engineering T-cells to recognize and kill cancer, otherwise known as chimeric antigen receptor T-cells, or CAR-Ts, will be busy at the ASCO annual meeting in June.